Seres Therapeutics (MCRB) Net Margin (2016 - 2026)

Seres Therapeutics has disclosed Net Margin across 10 years of filings, most recently posting 2865.76% for Q2 2026.

• In Q2 2026, Net Margin changed N/A year-over-year to 2865.76%; the TTM figure through Jun 2026 stood at 4379.45% (changed N/A YoY), while the FY2025 annual figure was 11627.88%, changed N/A from the prior year.
• Net Margin came in at 2865.76% for Q2 2026 at Seres Therapeutics, up from 5749.16% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 36.81% in Q2 2023 to a low of 15759.03% in Q3 2023.
• Average Net Margin over 4 years is 4965.27%, with a median of 4045.95% recorded in 2022.
• The largest YoY upside for Net Margin was 533541 bps in 2023 against a maximum downside of 1401777 bps in 2023.
• Over 4 years, Net Margin stood at 225.33% in 2022, then soared by 115 bps to 32.93% in 2023, then plunged by 13224 bps to 4322.37% in 2025, then jumped by 34 bps to 2865.76% in 2026.
• Per Business Quant data, the three most recent Net Margin figures were 2865.76% in Q2 2026, 5749.16% in Q1 2026, and 4322.37% in Q4 2025.